EGFR and non-small cell lung carcinoma: Therapies targeting specific genomic alterations, such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) fusions, have greatly improved NSCLC management [4].